NCT05570643 (LPS-BM) is a NA clinical trial of LPS in Sepsis, Endotoxemia, Immunosuppression, sponsored by Radboud University Medical Center.

Who is sponsoring NCT05570643?

NCT05570643 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT05570643?

Interventions in NCT05570643: LPS, Placebo.

What condition does NCT05570643 study?

NCT05570643 studies Sepsis, Endotoxemia, Immunosuppression.

Is NCT05570643 still recruiting?

NCT05570643 is currently completed. Last updated 6 October 2022.

Last reviewed 2022-10-06 · How we verify

NCT05570643: LPS-BM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Human Endotoxemia on Functional Capacity of Hematopoietic Stem and Progenitor Cells

Completed NA Last updated 6 October 2022

What this trial tests

NA trial testing LPS in Sepsis, Endotoxemia, Immunosuppression in 12 participants. Completed in 28 June 2018.

Timeline

5 January 2018

Primary endpoint
28 June 2018

28 June 2018

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	12
Start date	5 January 2018
Primary completion	28 June 2018
Estimated completion	28 June 2018
Sites	1 location across Netherlands

Drugs / interventions tested

LPS — full drug profile →
Placebo

Conditions studied

Sepsis, Endotoxemia, Immunosuppression — all drugs for Sepsis, Endotoxemia, Immunosuppression →

Sponsor

Radboud University Medical Center

Who can join

Adults 18 to 35, male only, with Sepsis, Endotoxemia, Immunosuppression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We will investigate whether human endotoxemia induces changes in human bone marrow cells and their downstream effector cells. To comprehensively investigate underlying mechanisms behind functional and transcriptional changes in these cell types, we will use state-of-the-art systems biology techniques, including single cell transcriptomics (epi)genetics, and metabolomics.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Systemic inflammation impairs human myelopoiesis and interferon I responses
Keramati F, Leijte GP, Bruse N, Grondman I, et al · · 2022 · DOI 10.1101/2022.10.06.22280312

Verify or expand the search:

Other trials of LPS

Trials testing the same drug.

NCT03271814 — Brain Biomarker on Inflammation Response · Phase 1 · withdrawn
NCT03953196 — A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants · EARLY_PHASE1 · completed
NCT04057807 — Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microgl · EARLY_PHASE1 · completed
NCT03426995 — First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in B · Phase 1 · terminated
NCT01587807 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK199 · Phase 1 · completed

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05570643 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 6 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05570643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing